美国 · SEC FORM 4
Tarsus Pharmaceuticals, Inc.
TARS · Nasdaq · CIK 0001819790 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
31 同一窗口内观察到的 Form 4 交易行
20 sales · 11 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 5 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2023-12-15 · Goldberg Andrew D..
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 6,070,928
- 上期报告
- 6,127,884
- 日均成交量
- 732,012
- 回补天数
- 8.3
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2023-12-15 | Goldberg Andrew D. | 买入 (P) | Common Stock | 1,000 | USD 18.96 | USD 18,960 | SEC 申报 ↗ |
| 2023-08-15 | Lin Elizabeth Yeu | 买入 (P) | Common Stock | 9,506 | USD 16.80 | USD 159,701 | SEC 申报 ↗ |
| 2022-09-14 | Lin Elizabeth Yeu | 买入 (P) | Common Stock | 18,400 | USD 16.12 | USD 296,606 | SEC 申报 ↗ |
| 2022-05-05 | Ackermann Michael | 买入 (P) | Common Stock | 100,000 | USD 13.50 | USD 1,350,000 | SEC 申报 ↗ |
| 2020-10-20 | Vivo Capital Fund IX, L.P.; Vivo Capital IX, LLC | 买入 (P) | Common Stock | 250,000 | USD 16.00 | USD 4,000,000 | SEC 申报 ↗ |
| 2020-10-20 | Tester Jason E. | 买入 (P) | Common Stock | 171,875 | USD 16.00 | USD 2,750,000 | SEC 申报 ↗ |
| 2020-10-20 | Horowitz Limited Partnership VIII | 买入 (P) | Common Stock | 184,375 | USD 16.00 | USD 2,950,000 | SEC 申报 ↗ |
| 2020-10-20 | FHMLS IX, L.L.C.; FHMLS IX, L.P.; Frazier Life Sciences IX, L.P.; Heron Patrick J; Topper James N | 买入 (P) | Common Stock | 312,500 | USD 16.00 | USD 5,000,000 | SEC 申报 ↗ |
Form 4 申报证据
82 transaction lines in the latest 365-day window; 382 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | YARNO WENDY L | 期权行权/转换 (M) | Common Stock | 302 | USD — | USD — | SEC 申报 ↗ |
| 2026-09-15 | PYOTT DAVID E I | 期权行权/转换 (M) | Common Stock | 201 | USD — | USD — | SEC 申报 ↗ |
| 2026-09-15 | LINK WILLIAM J PHD | 卖出 (S) | Common Stock | 12,500 | USD 78.38 | USD 979,744 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-09-15 | YARNO WENDY L | 期权行权/转换 (M) | Common Stock | 302 | USD — | USD — | SEC 申报 ↗ |
| 2026-09-15 | PYOTT DAVID E I | 期权行权/转换 (M) | Common Stock | 201 | USD — | USD — | SEC 申报 ↗ |
| 2026-09-15 | LINK WILLIAM J PHD | 卖出 (S) | Common Stock | 12,500 | USD 78.38 | USD 979,744 | SEC 申报 ↗ |
| 2026-09-15 | LINK WILLIAM J PHD | 期权行权/转换 (M) | Common Stock | 201 | USD — | USD — | SEC 申报 ↗ |
| 2026-09-04 | Neervannan Seshadri | 卖出 (S) | Common Stock | 4,564 | USD 85.00 | USD 387,940 | SEC 申报 ↗ |
| 2026-09-04 | Lin Elizabeth Yeu | 卖出 (S) | Common Stock | 13,953 | USD 87.50 | USD 1,220,885 | SEC 申报 ↗ |
| 2026-09-04 | Azamian Bobak R. | 卖出 (S) | Common Stock | 10,000 | USD 90.56 | USD 905,600 | SEC 申报 ↗ |
| 2026-09-02 | Lin Elizabeth Yeu | 卖出 (S) | Common Stock | 6,977 | USD 80.00 | USD 558,160 | SEC 申报 ↗ |
| 2026-09-02 | Azamian Bobak R. | 卖出 (S) | Common Stock | 10,000 | USD 80.06 | USD 800,600 | SEC 申报 ↗ |
| 2026-09-01 | Lin Elizabeth Yeu | 卖出 (S) | Common Stock | 4,601 | USD 73.86 | USD 339,830 | SEC 申报 ↗ |
| 2026-06-17 | Azamian Bobak R. | 卖出 (S) | Common Stock | 10,000 | USD 61.55 | USD 615,488 | SEC 申报 ↗ |
| 2026-06-16 | Farrow Jeffrey S | 卖出 (S) | Common Stock | 14,396 | USD 60.95 | USD 877,436 | SEC 申报 ↗ |
| 2026-06-15 | LINK WILLIAM J PHD | 卖出 (S) | Common Stock | 12,500 | USD 62.12 | USD 776,495 | SEC 申报 ↗ |
| 2026-06-15 | Goodrich Katherine | 卖出 (S) | Common Stock | 2,954 | USD 62.08 | USD 183,384 | SEC 申报 ↗ |
| 2026-06-15 | Farrow Jeffrey S | 期权行权/转换 (M) | Common Stock | 27,881 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-12 | YARNO WENDY L | 期权行权/转换 (M) | Common Stock | 2,954 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-12 | Morrison Scott W | 期权行权/转换 (M) | Common Stock | 2,954 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-12 | LINK WILLIAM J PHD | 期权行权/转换 (M) | Common Stock | 2,954 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-12 | Goodrich Katherine | 期权行权/转换 (M) | Common Stock | 2,954 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-12 | Goldberg Andrew D. | 期权行权/转换 (M) | Common Stock | 2,954 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-12 | CHAUDHURI BHASKAR | 期权行权/转换 (M) | Common Stock | 2,954 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-24 | PYOTT DAVID E I | 期权行权/转换 (M) | Common Stock | 1,383 | USD — | USD — | SEC 申报 ↗ |
| 2026-03-20 | Neervannan Seshadri | 卖出 (S) | Common Stock | 2,989 | USD 66.75 | USD 199,516 | SEC 申报 ↗ |
| 2026-03-19 | Whitfield Dianne C. | 卖出 (S) | Common Stock | 4,174 | USD 67.00 | USD 279,658 | SEC 申报 ↗ |
| 2026-03-19 | Wahl Bryan | 卖出 (S) | Common Stock | 4,231 | USD 67.00 | USD 283,477 | SEC 申报 ↗ |
| 2026-03-19 | Neervannan Seshadri | 卖出 (S) | Common Stock | 4,589 | USD 67.00 | USD 307,463 | SEC 申报 ↗ |
| 2026-03-19 | Mottiwala Aziz | 卖出 (S) | Common Stock | 4,440 | USD 67.00 | USD 297,480 | SEC 申报 ↗ |
| 2026-03-19 | Lin Elizabeth Yeu | 卖出 (S) | Common Stock | 390 | USD 67.00 | USD 26,130 | SEC 申报 ↗ |
| 2026-03-19 | Farrow Jeffrey S | 卖出 (S) | Common Stock | 2,186 | USD 67.00 | USD 146,462 | SEC 申报 ↗ |
| 2026-03-19 | Azamian Bobak R. | 卖出 (S) | Common Stock | 11,964 | USD 67.00 | USD 801,588 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | TARS |
| CIK | 0001819790 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 382 transaction lines from 2020-10-20 to 2026-09-15 11 P purchase lines · 259 S sale lines · 112 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.